🌍·23h agoResearch
Comment on ‘Lebrikizumab provides stable skin response with no or minimal fluctuations for up to 2 years in patients with atopic dermatitis’
Publisher
C
Crossref
Global
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- Crossref
- Region
- Global
- Scope
- Research
- Published
- July 13, 2026
- Language
- EN
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on doi.org
Leave the platform to read the original full article on the publisher site.
Source: Crossref
Scope: Research
Related coverage
More related coverage
UNLP Health Sciences/6h ago
Se realizó la primera reunión del Consejo Social de la gestión 2026-2030
UNLP Health Sciences/6h ago
Tauber recorrió las obras avanzadas de la facultad de Trabajo Social
UNLP Health Sciences/6h ago
La UNLP celebró el día de la Independencia
AHA Newsroom/7h ago